NEWSLINE

Document Sample
NEWSLINE
000A18_MPR_0210.qxp 1/27/2010 3:20 PM Page 1









NEWSLINE

Highlights of recent developments

Sumavel DosePro available H1N1 vaccine monitoring Bacitracin Oph. Ointment

The FDA has issued a letter

to update healthcare profes-

sionals on the FDA/CDC

experience with the H1N1

vaccination program and to

provide details on the cur-

rent vaccine safety monitor-

ing program. The FDA and

CDC are assessing H1N1

vaccine safety on a continu-

Zogenix and Astellas have ing basis and have published Fera has made Bacitracin

made available Sumavel a report describing the safety ophthalmic ointment readily

DosePro (sumatriptan profile of H1N1 vaccines in available again. Previously,

injection), a selective the U.S. No substantial dif- only a limited quantity

5-HT1B/1D receptor agonist ferences between H1N1 and of this prescription anti-

in a needle-free delivery seasonal influenza vaccines infective ophthalmic had

system, for the acute treat- were noted in the propor- been available. Bacitracin

ment of migraine attacks, tion or types of serious ophthalmic ointment is indi-

with or without aura, and adverse events reported. cated to treat susceptible

the acute treatment of No increase in any of the superficial ocular infections

cluster headache episodes. preselected adverse events involving the conjunctiva

Sumavel DosePro is avail- under surveillance (eg, and/or cornea.

able as a 6mg/0.5mL single- Guillain-Barré syndrome) For more information

use, disposable injection. has been seen in Vaccine call (414) 434-6604.

For more information Safety Datalink data.

call (866) ZOGENIX. For more information visit Spiriva HandiHaler update

www.fda.gov/NewsEvents/ The FDA announced that

Adrenaclick Auto-injector PublicHealthFocus/ucm197 data from a recent review of

Sciele Pharma announced 733.htm. Spiriva HandiHaler (tiotro-

that Adrenaclick (epineph- pium dry powder for inhala-

rine auto-injector) is avail- Sulfite-free sfRowasa tion, from Boehringer

able for the treatment of sfRowasa (mesalamine Ingelheim) do not support

severe allergic reactions rectal suspension), a sulfite- an increased risk of stroke,

(Type I). These reactions free formulation of Rowasa heart attack, or death. This

include anaphylaxis to sting- has been made available to communication is based on a

ing and biting insects, aller- treat active mild to moder- review of the Understanding

gen immunotherapy, foods, ate di

By registering with docstoc.com you agree to our
privacy policy and terms of service

Successfully added document to cart!

Successfully added document to cart!